Lidocain Baxter (Lidocaine Hydrochloride)

Lidocaine blocks voltage‑gated sodium channels on nerve and cardiac cells, preventing the influx of sodium ions that initiates action potentials. This interruption stops nerve impulse transmission, producing loss of sensation, and reduces abnormal cardiac excitability, helping to control ventricular arrhythmias.

The dosage of Lidocain Baxter is individualized by the prescribing clinician based on the specific indication, patient weight, age, and clinical condition. Healthcare professionals determine the appropriate dose and infusion rate according to established guidelines and patient response.

Lidocaine’s pregnancy category is listed as unknown, and safety data for breastfeeding are limited. Use during pregnancy or lactation should only occur when the potential therapeutic benefit justifies any potential risk to the fetus or infant, and it must be decided by the treating physician.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and the necessary import documentation.

Lidocaine has a relatively rapid onset and intermediate duration compared with agents such as bupivacaine, which lasts longer but has a slower onset. Its safety profile is well‑characterized, and it is often preferred for short‑procedures and for intravenous anti‑arrhythmic use, whereas bupivacaine is chosen for prolonged regional blocks.

Lidocain Baxter should be stored at room temperature, below 25 °C, in its original packaging. Protect the solution from direct light and moisture. Do not freeze. Inspect the container for particulate matter or discoloration before use and discard if any abnormalities are observed.

Lidocain Baxter is supplied as a sterile injectable solution for intravenous administration. It is typically given as a bolus or continuous infusion, depending on the clinical indication, and must be administered by qualified healthcare personnel in a setting where cardiac monitoring is available.

The most serious adverse events include severe allergic reactions (anaphylaxis), cardiac arrest or profound bradycardia, seizures, respiratory depression, and worsening of existing arrhythmias. Immediate medical intervention is required if any of these events occur.

Lidocain Baxter is contraindicated in patients with a known hypersensitivity to lidocaine or other amide‑type local anesthetics, those with severe heart block or uncontrolled conduction disorders, and individuals with significant hepatic impairment without dose adjustment. Clinicians should evaluate each patient’s medical history before prescribing.